In this video, Charu Aggarwal, MD, MPH, the Leslye M. Heisler Professor for Lung Cancer Excellence at University of ...
New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relacorilant plus nab-paclitaxel showed a PFS benefit in patients with ...
Immune checkpoint inhibitors have shown efficacy in other HPV-related cancers, so a phase 2 trial tested avelumab treatment for locally advanced or metastatic penile cancer.
Data from an exploratory analysis of the pivotal phase 3 MIRASOL trial (NCT04209855) were recently unveiled at the 2025 European Society for Medical Oncology (ESMO) Congress, opening a broader ...
Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation has announced a new Phase 3 study titled ‘A Phase 3, ...
NovoCure Ltd. (($NVCR)) announced an update on their ongoing clinical study. The LUNAR-2 study by NovoCure Ltd. aims to evaluate the effectiveness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback